Clinical Trial Details
EORTC-55092-GCG
Back to Clinical Trials Database
Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma.
Trial Status | Closed to Patient Entry |
---|---|
Dates |
Date of activation: 20-Jul-2012 Date Step1 close: 16-May-2018 |
Data management at EORTC | Yes |
Design |
Phase 1-2 Randomized open label |
Targeted Sample size | EORTC Groups: 88 - All Groups: 88 |
Treatment |
Drug Bevacizumab, Carboplatin, Paclitaxel, Pazopanib |
Study Staff |
Corneel Coens (Statistician) , EORTC Headquarters, Brussels Sara Meloen (Pharmacovigilance Manager) , EORTC Headquarters, Brussels Ellen Peeters (Senior Clinical Operations Manager) , EORTC Headquarters, Brussels Jelle Stans (Regulatory Affairs Manager) , EORTC Headquarters, Brussels |
Type of cancer |
Ovarian Fallopian Tube |
Participating groups | EORTC Gynecological Cancer Group |
Recruiting centers |
C.H.U. Sart-Tilman (Liege, Belgium) Centre Hospitalier Regional De La Citadelle (Liege, Belgium) Erasmus MC Hospital (Rotterdam, Netherlands) Hospital Universitario 12 De Octubre (Madrid, Spain) Hospital Universitario San Carlos (Madrid, Spain) ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) (Badalona - (Barcelona), Spain) Institut Jules Bordet (Anderlecht, Belgium) Radboud University Medical Center Nijmegen (Nijmegen, Netherlands) |
Protocol summary | http://clinicaltrials.gov/study/NCT01402271 |
NCT number | NCT01402271 |
EudraCT | 2010-024077-39 |
Financial Support | Educational Grant |